Q
1.33
0.25 (23.15%)
| Previous Close | 1.08 |
| Open | 1.10 |
| Volume | 666,008 |
| Avg. Volume (3M) | 33,296 |
| Market Cap | 266,829,072 |
| Price / Sales | 0.790 |
| Price / Book | 1.20 |
| 52 Weeks Range | |
| Earnings Date | 11 Feb 2026 |
| Profit Margin | -26.32% |
| Operating Margin (TTM) | -5.41% |
| Diluted EPS (TTM) | -0.200 |
| Quarterly Revenue Growth (YOY) | -56.90% |
| Quarterly Earnings Growth (YOY) | -16.40% |
| Total Debt/Equity (MRQ) | 0.22% |
| Current Ratio (MRQ) | 7.05 |
| Operating Cash Flow (TTM) | 2.96 M |
| Levered Free Cash Flow (TTM) | 3.36 M |
| Return on Assets (TTM) | -3.84% |
| Return on Equity (TTM) | -16.52% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | BGM Group Ltd. | - | - |
AIStockmoo Score
0.1
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.13 |
|
BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Mid Value |
| % Held by Insiders | 7.29% |
No data within this time range.
No data within this time range.
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 27 Feb 2023 | - | 06 Mar 2023 | 0.05 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2023 | 0.050 | 1 | 1.30 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |